Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : SPR720
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Spero Provides Phase 2a Interim Results and Business Update On SPR720
Details : SPR720 is an oral, chemically stable phosphate ester prodrug in vivo to SPR719, it is being evaluated for the Non Tuberculous Mycobacterial-Pulmonary Disease.
Brand Name : SPR720
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 29, 2024
Lead Product(s) : SPR720
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : SPR720
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Spero Therapeutics Provides Update on SPR720 Phase 2a Clinical Trial
Details : United States Food and Drug Administration (FDA) informed Spero that a clinical hold has been placed on its Phase 2a clinical trial of SPR720, Spero’s investigational oral antimicrobial agent being evaluated in patients with nontuberculous mycobacteria...
Brand Name : SPR720
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 05, 2021
Lead Product(s) : SPR720
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : SPR720
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Spero Therapeutics Announces FDA Acceptance of IND Application for SPR720
Details : The planned Phase 2a clinical trial will be a multi-center, partially blinded, placebo-controlled proof-of-concept clinical trial of SPR720 that will enroll approximately 90 treatment inexperienced patients with NTM pulmonary disease due to Mycobacterium...
Brand Name : SPR720
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 31, 2020
Lead Product(s) : SPR720
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?